1. Anon. U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine: Guidance for Industry, Bioanalytical Method Validation, 2001.
2. Anon. European Medicines Agency (EMEA): Guideline on bioanalytical method validation, 2011.
3. Benchaoui H.A., Nowakowski M., Sherington J., Rowan T.G., Sunderland S.J.: Pharmacokinetics and lung tissue concentrations of tulathromycin in swine. J Vet Pharmacol
1. Chopra, I., Roberts, M. (2001). Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 65 (2): 232-260. https://doi.org/10.1128/MMBR.65.2.232-260.2001 PMid:11381101 PMCid:PMC99026
2. Valentín, S., Morales, A., Sánchez, J.L., Rivera, A. (2009). Safety and efficacy of doxycycline in the treatment of rosacea. Clin Cosmet Investig Dermatol. 2, 129-140. PMid:21436975 PMCid:PMC3047926
3. Agwuh, K. N., MacGowan, A. (2006). Pharmacokinetics and
Anthony Singer, Eleni Markoutsa, Alya Limayem, Subhra Mohapatra and Shyam S. Mohapatra
Biomedical Nanotechnology (BNT) has rapidly become a revolutionary force that is driving innovation in the medical field. BNT is a subclass of nanotechnology (NT), and often operates in cohort with other subclasses, such as mechanical or electrical NT for the development of diagnostic assays, therapeutic implants, nano-scale imaging systems, and medical machinery. BNT is generating solutions to many conventional challenges through the development of enhanced therapeutic delivery systems, diagnostic techniques, and theranostic therapies. Therapeutically, BNT has generated many novel nanocarriers (NCs) that each express specifically designed physiochemical properties that optimize their desired pharmacokinetic profile. NCs are also being integrated into nanoscale platforms that further enhance their delivery by controlling and prolonging their release profile. Nano-platforms are also proving to be highly efficient in tissue regeneration when combined with the appropriate growth factors. Regarding diagnostics, NCs are being designed to perform targeted delivery of luminescent tags and contrast agents that enhance the NC -aided imaging capabilities and resulting diagnostic accuracy of the presence of diseased cells. This technology has also been advancing the ability for surgeons to practice true precision surgical techniques. Incorporating therapeutic and diagnostic NC-components within a single NC can facilitate both functions, referred to as theranostics, which facilitates real-time in vivo tracking and observation of drug release events via enhanced imaging. Additionally, stimuli-responsive theranostic NCs are quickly developing as vectors for tumor ablation therapies by providing a model that facilitates the location of cancer cells for the application of an external stimulus. Overall, BNT is an interdisciplinary approach towards health care, and has the potential to significantly improve the quality of life for humanity by significantly decreasing the treatment burden for patients, and by providing non-invasive therapeutics that confer enhanced therapeutic efficiency and safety
1. Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63: 492-498, 1986.
2. Nauck MA, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (noninsulin- dependent) diabetes. Diabetologia 29: 46-52, 1986.
3. Vildagliptin - summary of product characteristics, 2012.
4. He Y-L. Clinical pharmacokinetics and pharmacodynamics of
Małgorzata Gbylik-Sikorska, Andrzej Posyniak, Tomasz Śniegocki, Bartosz Sell, Anna Gajda, Grzegorz Tomczyk and Jan Żmudzki
1982, 4, 115–135.
10. De Ruyck H., De Ridder H., Van Renterghem R., Van Wambeke F.: Validation of HPLC method of analysis of tetracycline residues in eggs and broiler meat and its application to a feeding trial. Food Addit Contam Part A 1999, 16, 47–56.
11. El-Gendi A.Y., Atef M., Amer A.M., Kamel G.M.: Pharmacokinetic and tissue distribution of doxycycline in broiler chickens pretreated with either: diclazuril or halofuginon. Food Chem Toxicol 2010, 48, 3209–3214.
12. Ershov E., Bellaiche M., Hanji V., Soback S., Gips M., Shlosberg A.: Interaction
H. Bártíková, L. Skálová, J. Lamka, B. Szotáková and M. Várady
pharmacokinetics. Acta Tropica, 86: 141–159 http://dx.doi.org/10.1016/S0001-706X(03)00031-7
 Dobson, R. J., Griffiths, D. A., Donald, A. D., Waller, P. J. (1987): A genetic model describing the evolution of levamisole resistance in Trichostrongylus colubriformis, a nematode parasite of sheep. IMA J. Appl. Math., 4: 279–293 http://dx.doi.org/10.1093/imammb/4.4.279
 Hubert, J., Kerboeuf, D. (1992): A microlarval development assay for the detection of anthelmintic resistance in sheep nematodes. Vet. Rec., 130: 442–446 http
Ralica Kyuchukova, Anelia Milanova, Aleksandra Daskalova, Deyan Stratev, Lubomir Lashev and Alexander Pavlov
partition coefficients of feed contaminants. Book of Abstracts. 2 nd Feed for Health Conference, p. 48. Tromso, Norway
4. Liang, J., Li, J., Zhao, F., Liu, P., Chang, Z. (2012). Pharmacokinetics and tissue behavior of enrofloxacin and its metabolite ciprofloxacin in turbot Scophthalmus maximus at two water temperatures. Chinese J. Oceanol. Limnol. 30, 644-653. http://dx.doi.org/10.1007/s00343-012-1228-2
5. Alfredsson, G., Ohlsson, A. (1998). Stability of sulphonamide drugs in meat during storage. Food Addit. Contam. 15, 302-306. http://dx.doi.org/10
Anna Bogacz, Donata Deka-Pawlik, Joanna Bartkowiak-Wieczorek, Monika Karasiewicz, Radosław Kujawski, Aleksandra Kowalska, Aleksandra Chałas, Bogusław Czerny, Edmund Grześkowiak and Przemysław M. Mrozikiewicz
Pharmacol Exp Ther 2000; 294:88-95.
24. Bilia AR, Gallori S, Vincieri FF. St. John’s wort and depression: efficacy, safety and tolerability - an update. Life Sci 2002; 70:3077-96.
25. Calapai G, Crupi A, Firenzuoli F et al. Serotonin, norepinephrine and dopamine involvement in the antidepressant action of Hypericum perforatum. Pharmacopsych 2001; 34:45-9.
26. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD. Effect of St John‘s wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002; 71
Anna Bogacz, Monika Karasiewicz, Joanna Bartkowiak-Wieczorek, Marcin Ożarowski, Agnieszka Seremak-Mrozikiewicz, Radosław Kujawski, Przemysław Ł. Mikołajczak, Beata Mrozikiewicz-Rakowska, Teresa Bobkiewicz-Kozłowska, Bogusław Czerny, Edmund Grześkowiak and Przemysław M. Mrozikiewicz
. Pharmacokinetics of tea catechins after ingestion of green tea and (-)- epigallocatechin-3 gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev 2002; 11:1025-1032.
19. Bu-Abbas A, Clifford MN, Walker R, Ioannides C. Selective induction of rat hepatic CYP1 proteins and of peroxisomal proliferation by green tea. Carcinogenesis 1994; 15:2575-2579.
20. Maliakal PP, Coville PF, Wanwimolruk S. Tea consumption modulates hepatic drug metabolizing enzymes in Wistar rats. J Pharm Pharmacol 2001